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Abstract
The fibroblast growth factors [Fgfs (murine), FGFs (human)] constitute a large family of
ligands that signal through a class of cell-surface tyrosine kinase receptors. Fgf signalling
has been associated in vitro with cellular differentiation as well as mitogenic and motogenic
responses.  In vivo, Fgfs are critical for animal development, and some have potent
angiogenic properties. Several Fgfs have been identified as oncogenes in murine mammary
cancer, where their deregulation is associated with proviral insertions of the mouse
mammary tumour virus (MMTV). Thus, in some mammary tumours of MMTV-infected mouse
strains, integration of viral genomic DNA into the somatic DNA of mammary epithelial cells
was found to have caused the inappropriate expression of members of this family of growth
factors. Although examination of human breast cancers has shown an altered expression of
FGFs or of their receptors in some tumours, their role in the causation of breast disease is
unclear and remains controversial.
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Introduction
There is a long history linking the inappropriate expression
of Fgfs with breast cancer development. The evidence for
their involvement in murine mammary cancer is strong, but
in the human disease the evidence is weaker and relies
heavily upon analogy with murine models to underpin the
somewhat conflicting findings. Nevertheless, Fgfs show a
multitude of properties in vitro that suggest that they have
the potential to contribute to the induction, progression
and metastasis of breast cancer. This short review pro-
vides an introduction to Fgfs, Fgf receptors, their role in
murine mammary cancer and the evidence for their associ-
ation with human breast cancer. The acronyms ‘Fgf’ and
‘FGF’ refer to the murine and human ligands, respectively.
Signalling through fibroblast growth factors
and their receptors
In mammals, the Fgfs constitute a large family of about 20
structurally homologous ligands, which transduce signals
through a class of cell-surface tyrosine kinase receptors
(for review [1–4]). Most Fgfs are secreted polypeptides
that typically have an amino-terminal signal sequence for
export through the constitutive secretory pathway. Two
notable exceptions are Fgf-1 and Fgf-2, however, which
have a nuclear as well as a cytoplasmic localization and
are secreted by novel but poorly understood mechanisms
[5–10]. Fgfs also bind with a relatively high affinity to
heparan sulphates, which in general are present as cova-
lently linked side chains on cell-surface proteoglycans.Breast Cancer Research    Vol 2 No 3 Dickson et al
Thus, signal transduction requires the binding of Fgf to
both heparan sulphate and Fgf receptor, to form a ternary
signalling complex [11]. Because most cells have an
abundance of proteoglycans on their surface, these cell-
surface molecules also serve to limit the diffusion of
secreted Fgfs to predominantly adjacent cells. Hence,
these ligands function as important autocrine and
paracrine signalling molecules.
The Fgf receptors are encoded by four genes (Fgfr-1 to
Fgfr-4), but because of alternative splicing of Fgfr-1,
Fgfr-2 and Fgfr-3, seven prototype receptors are gener-
ated [2,3]. Each prototype receptor has a different ligand-
binding capacity and tissue distribution [12•,13–17]. The
receptors are composed of an external part that consists
of two or three immunoglobulin-like domains, and a trans-
membrane element that extends to a cytoplasmic tyrosine
kinase (Fig. 1). The two membrane proximal immunoglobu-
lin-like domains (loops 2 and 3) comprise the ligand-
binding domain. Upon binding of the ligand, it appears
that the Fgf receptor complexes dimerize, in conjunction
with a heparan sulphate moiety, and the tyrosine kinase is
activated through autophosphorylation [18••]. These
events facilitate the binding of second messenger pro-
teins, which in turn activate various intracellular signalling
pathways (for review [4]). It should be noted, however,
that additional alternative splicing, that does not alter the
Fgf-binding domain, generates several other Fgf receptor
forms that are assumed to serve some as yet undefined
function. For example, it is common to find Fgf receptors
with only the second and third immunoglobulin-like
domains, which may or may not extend to the very acidic
region (acid box) that lies between immunoglobulin
loops 1 and 2 (see Fig. 1).
In culture, the cellular consequences of Fgf stimulation are
quite varied. For example, many are broad-spectrum mito-
gens, and some induce cell motility, or alter the state of
cellular differentiation (for review [1,3]). In vivo, some Fgfs
have potent angiogenic properties, and others have been
implicated in tissue remodeling, such as that required for
wound repair [19]. The majority of Fgfs are expressed
during embryonic development in precise, but often over-
lapping spatially and temporally restricted patterns
[20,21]. Thus, it has become evident that the Fgfs have
essential functions in many aspects of animal develop-
ment, which range from myoblast migration in
Caenorhabolitis elegans and tracheal formation in
Drosophila, to inductive and patterning roles in formation
of the mammalian limb [20–23]. Moreover, genetic linkage
analysis has found that three Fgf receptor genes are the
underlying cause of several human skeletal dysplasias and
a number of autosomal-dominant craniosynostosis syn-
dromes (for review [24]). Therefore, from their known
properties and functions, it might be predicted that dereg-
ulation of this intercellular signalling system could con-
tribute to other human pathologies, including the growth,
survival and metastatic spread of tumours.
Identification of fibroblast growth factors as
potent oncogenes for the mammary gland
The females of several inbred strains of mice show a very
high incidence of mammary cancer. For most of these
mouse strains, the major factor that predisposes the mice
to mammary tumours is the presence of the MMTV. This
retrovirus replicates primarily in the mammary epithelium,
shedding its progeny into the milk of lactating mothers, so
that the virus is acquired by their offspring as a congenital
infection. Because retroviruses replicate through a DNA
intermediate that integrates into the host cell genome, all
retroviruses can be considered as insertional mutagens.
The viral DNA appears to integrate in an essentially
random manner, so that only on rare occasions does it
cause a mutation that leads to a growth advantage for an
infected cell, with the potential for it to ultimately progress
to frank neoplasia (Fig. 2). Such events are likely to be
extremely rare for any individually infected cell, but very
large numbers of cells in the mouse mammary gland
become infected, so most female mice will by chance
eventually contain a cell that has acquired an oncogenic
mutation.
A number of studies have shown that the integrated virus
alters the cell phenotype by causing inappropriate tran-
scriptional activation of an adjacent host gene. This usually
occurs through the action of its potent transcriptional
enhancer elements or by bringing the transcription of the
Figure 1
Fgf receptor structure and Fgf signalling. Structural domains of an Fgf
receptor are shown on the right of the panel. Fgf signal transduction is
initiated upon binding the Fgf ligand in conjunction with heparan
sulphate to form a ternary complex. The result is autophosphorylation
and activation of the tyrosine kinase, which facilitates second
messenger signalling through phosphotyrosine-dependent and
-independent interactions with the cytoplasmic portion of the receptor.http://breast-cancer-research.com/content/2/3/191
host gene under the control of the viral promoter. These
types of mutation are dominant in the heterozygous condi-
tion. An advantage of the MMTV model of mammary
cancer is that the provirus remains at the mutation site,
and thereby acts as a tag to identify the linked somatic
gene that is contributing to tumour induction. Hence,
proviruses that locate to the same locus in several inde-
pendent tumours mark the proximity of the candidate
oncogene. Detailed analysis of proviral integration sites
has led to the identification of several virally activated
proto-oncogenes, that include three members of the Fgf
family: Int-2/Fgf-3, hst-1/Fgf-4 and Fgf-8 (Fig. 2, Table 1).
Historically, the first proto-oncogene to be identified from
analysis of MMTV-induced tumours was Int-1/Wnt-1,
which was later found to be a homologue of the
Drosophila segmentation polarity gene wingless [25,26].
This was closely followed by the discovery of Fgf-3 at a
second distinct locus [27]. Subsequently, many tumours
were found to have MMTV insertions at both Wnt-1 and
Fgf-3 [28]. Because insertions are thought to be largely a
chance event, the discovery in individual tumours of inser-
tions at both loci suggested that there must be a strong
selection for both genes in tumour induction. The potent
oncogenic effect of Wnt-1 and Fgf-3 was substantiated
when transgenic mice, constitutively expressing either
gene, were observed to develop multiple mammary
tumours earlier than the original inbred strains harbouring
MMTV [29–32]. Moreover, when a transgenic line
expressing Wnt-1 was infected with MMTV, the mammary
tumours that arose in these mice were found to have viral
insertions at Fgf-3 or the adjacent Fgf-4 or Fgf-8 locus,
but not in the Wnt-1 or Wnt-3 loci [33–35]. This provided
additional evidence for co-operation between these two
oncogene families in mammary tumorigenesis.
Fibroblast growth factors and their receptors
in human breast cancer
The identification of Fgfs as oncogenes in murine
mammary cancer prompted the examination of human
breast tumours for alterations in the structure and expres-
sion of these loci. Interestingly, Fgf-3 and Fgf-4, which are
only a few kilobases apart on mouse chromosome 7, show
synteny with human chromosome 11 band q13. Examina-
tion of the FGF-3/FGF-4 locus by Southern blotting analy-
sis showed that approximately 15% of human breast
tumour DNA had readily detectable levels of somatic
amplification in this region. Analysis of RNA, however,
revealed that neither FGF-3 or FGF-4 were transcribed in
the vast majority of these tumours. Subsequently, the
cyclin D1 gene (CCND1) was found to be closely linked to
FGF-3/FGF-4, invariably forming part of the same ampli-
con. From studies carried out by several groups, there is
now a consensus that CCND1 is the important active
oncogene in this region, and is therefore implicated in
many human breast tumours (for review [36]). Thus, for
the great majority of human breast tumours showing
FGF-3/FGF-4 amplification, these genes are merely pas-
sengers on the same amplicon as CCND1 and are not
implicated in the disease process.
The introduction of reverse transcription polymerase chain
reaction procedures has led to the detection of a number
of FGFs and their receptors in normal and malignant
breast tissue [37]. These studies are not sufficient to
unambiguously implicate FGFs or their receptors as major
players in the development of breast cancers, but they are
suggestive of some involvement. FGF-2, which has angio-
genic properties, has been the most extensively investi-
gated member of the FGF family. The majority of studies
have been on small to modest numbers of tumours, and
the results are often conflicting. For example, some
reports indicate that an increased amount of FGF-2 can
be found in tumours compared with in normal breast
tissue [38,39•], whereas others find no difference [40] or
Figure 2
Proto-oncogene activation by insertional mutagenesis of MMTV. (a)
Insertion of viral genomic DNA into somatic cellular DNA in close
proximity of a silent oncogene. (b) Inserted proviral DNA induces the
transcription of the oncogene.
Table 1
Oncogenes identified as common targets for activation by
MMTV in mouse mammary tumours
Proto-oncogenes activated by MMTV References
Fgf-3 (Int-2) Peters et al 1983 [27]
Fgf-4 (hst-1) Peters et al 1989 [60]
Fgf-8 MacArthur et al 1995 [35]
Wnt-1 (Int-1) Nusse and Varmus 1982 [25]
Wnt-3 Roelink et al 1990 [61]
Wnt-10b Lee et al 1995 [58]
Notch-4 (Int-3) Gallahan et al 1987 [59]lower levels [41–43]. Some of these studies show an
association between higher FGF-2 levels and a better
prognosis, however [39•,40]. Interestingly, the study by
Smith et al [39•] examined the relationship between
FGF-2 levels and microvessel count, but found no evi-
dence for an angiogenic effect of FGF-2. Immunohisto-
chemistry shows that most FGF-2 in breast tumours is
found in association with the stromal component, and little
or none has been reported in the cancer cells [39•,44].
Similar studies that investigated the presence of FGF-1
have found it in normal and malignant breast tissue, and
again it appears to be reduced in the cancer cells
[37,45–47]. In contrast to the conspicuous absence in
human breast cancer of the two mouse mammary onco-
genes FGF-3 and FGF-4, the situation appears to be dif-
ferent for FGF-8. Both reverse transcription polymerase
chain reaction and in situ hybridization analyses indicate
that elevated levels of FGF-8 are associated with a small
subset of malignant breast tumours [48,49].
There are also a few reports that, in some breast cancers,
FGF receptor genes are amplified, with FGFR1 (approxi-
mately 20%) and FGFR4 (approximately 30%) both provid-
ing a significant number of cases [37,50,51]. In addition,
elevated expression of FGF receptors was detected using
ligand-binding studies with iodinated FGF-2 and immunolo-
calization with an antibody to FGFR1 [47,52]. At present,
although there are some intriguing correlations between
the expression of FGFs or their receptors in breast cancer,
the evidence that they play a major role is by no means
compelling. A recent study [53••], however, found that a
significant proportion of bladder and cervical carcinomas
harbour point mutations in FGFR3 that are similar to those
that underlie thanatophoric dysplasia, a rare but severe
skeletal abnormality of newborn children. Analysis of the
mutant receptors has shown that they have acquired ligand
independent activity [54–56]. Activating mutations of
FGFR1,  FGFR2 and  FGFR3 have also been found in some
craniosynostosis syndromes (for review [24]). Hence, it will
be important to determine whether similar somatic muta-
tions occur in breast cancers, thereby contributing to
deregulation of proliferation, differentiation or cell motility.
Conclusion
Studies to date clearly show that inappropriate Fgf sig-
nalling in the mouse mammary gland leads to hyperplastic
growth and eventually to frank neoplasia. Although there is
evidence that FGFs and their receptors can be aberrantly
expressed in human breast cancers, the findings between
groups are inconsistent and there is no overwhelming evi-
dence pointing to a major role for these molecules in
either growth stimulation, or as potentiators of angiogene-
sis. There are several reasons why the present data are
conflicting. The sample sizes analyzed are generally small,
whereas the variation within each group is quite large,
thereby reducing confidence in the conclusions. In some
cases the controls for the breast cancer group were
benign tumour samples, whereas for others tissue from
reduction mammoplasty was used, making direct compar-
isons between studies difficult.
Although there are at least 20 members of the FGF family,
the majority of studies have concentrated on FGF-1 and
FGF-2. Other members of the family are under investiga-
tion for their potential involvement in breast cancer,
however. Indeed, the results for FGF-8 suggest that it may
be an important cytokine in mammary cancer. There is also
good evidence that FGFR1 and FGFR4 are amplified in a
number of breast tumours. It is not clear, however,
whether amplification of these receptors contributes to
tumour development, because there is little information on
the expression and activity of these receptors. As most
gene amplifications extend over 1–2 Mb of DNA, they
often encompass several genes. Thus, the identity of a
potential oncogene cannot be established without a rigor-
ous analysis of the amplicon.
The role of FGF signalling in breast cancer remains con-
tentious. However, given the widespread occurrence of
this signalling pathway, with its diverse biological effects,
it would be surprising if it was not involved in at least a
subset of breast tumours. Two observations support the
likelihood of this: first, its well-established involvement in
murine mammary cancer; and second, the recent finding
that point mutations in FGFR3 have been detected in
bladder and cervical carcinomas. In breast tissue, FGFR2
appears to be important for normal mammary gland devel-
opment [57], but as yet there is no documented evidence
that activating point mutations of this or any other FGF
receptor occurs in human breast tumours.
References
Articles of particular interest have been highlighted as:
• of special interest
•• of outstanding interest
1. Basilico C, Moscatelli D: The FGF family of growth-factors and
oncogenes. Adv Cancer Res 1992, 59:115–165.
2. Johnson D, Williams L: Structural and functional diversity in the
FGF receptor multigene family. Adv Cancer Res 1993, 60:1–41.
3. McKeehan WL, Wang F, Kan M: The heparan-sulfate fibroblast
growth-factor family: diversity of structure and function. Prog
Nucleic Acid Res Mol Biol 1998, 59:135–176.
4. Klint P, Claesson-Welsh L: Signal transduction by fibroblast growth
factor receptors. Frontiers Biosci 1999, 4:165–177.
5. Bugler B, Amalric F, Prats H: Alternative initiation of translation
determines cytoplasmic or nuclear localization of basic fibroblast
growth factor. Mol Cell Biol 1991, 11:573–577.
6. Renko M, Quarto N, Morimoto T, Rifkin D: Nuclear and cytoplasmic
localization of different basic fibroblast growth factor species. J
Cell Physiol 1990, 144:108–114.
7. LaVallee TM, Tarantini F, Gamble S, et al: Synaptotagmin-1 is
required for fibroblast growth-factor-1 release. J Biol Chem 1998,
273:22217–22223.
Breast Cancer Research    Vol 2 No 3 Dickson et al8. Florkiewicz R, Anchin J, Baird A: The inhibition of fibroblast growth
factor-2 export by carenolides implies a novel function for the cat-
alytic subunit of Na+, K+-ATPase. J Biol Chem 1998, 273:544–551.
9. Tarantini F, LaVallee T, Jackson A, et al: The extravesicular domain
of synaptotagmin-1 is released with the latent fibroblast growth
factor-1 homodimer in response to heat shock. J Biol Chem 1998,
273:22209–22216.
10. Zhan X, Hu XG, Friedman S, MacIag T: Analysis of endogenous and
exogenous nuclear translocation of fibroblast growth factor-1 in
NIH3T3 cells. Biochem Biophys Res Commun 1992, 188:982–991.
11. Klagsbrun M, Baird A: A dual receptor system is required for basic
fibroblast growth factor activity. Cell 1991, 67:229–231.
12. Ornitz DM, Xu JS, Colvin JS, et al: Receptor specificity of the fibro-
• blast growth-factor family. J Biol Chem 1996, 271:15292–15297.
The interaction of all known mammalian Fgf receptor isoforms with a number of
Fgfs is presented, and the consequent level of receptor activation is compared.
13. Peters K, Werner S, Chen G, Williams L: Two FGF receptor genes
are differentially expressed in epithelial and mesenchymal tissues
during limb formation and organogenesis in the mouse. Develop-
ment 1992, 114:233–243.
14. Orr-Urtreger A, Bedford M, Burakova T, et al: Developmental local-
ization of the splicing alternatives of fibroblast growth-factor
receptor-2 (FGFR2). Dev Biol 1993, 158:475–486.
15. Peters K, Ornitz D, Werner S, Williams L: Unique expression pattern
of the fgf receptor-3 gene during mouse organogenesis. Dev Biol
1993, 155:423–430.
16. Partanen J, Armstrong E, Makela TP, et al: A novel endothelial-cell
surface-receptor tyrosine kinase with extracellular epidermal growth-
factor homology domains. Mol Cell Biol 1992, 12:1698–1707.
17. Stark K, McMahon J, McMahon A: FGFR-4, a new member of the
fibroblast growth factor receptor family, expressed in the defini-
tive endoderm and skeletal muscle lineages of the mouse. Devel-
opment 1991, 113:641–651.
18. Plontnikov A, Schlessinger J, Hubbard S, Mohammadi M: Struc-
•• tural basis of fgf receptor dimerization and activation. Cell 1999, 
98:641–650.
A structural analysis of Fgf binding to its receptor is presented, showing that
two Fgf molecules bind two receptor elements in such a configuration that
they form a positively charged groove that could accommodate the known
interaction with a heparan sulphate moiety. The paper also gives further
insight into the parameters that control Fgf binding specificity.
19. Werner S, Smola H, Liao X, et al: The function of KGF in morpho-
genesis of epithelium and reepithelialization of wounds. Science
1994, 266:819–822.
20. Yamaguchi TP, Rossant J: Fibroblast growth-factors in mammalian
development. Curr Opin Genet Dev 1995, 5:485–491.
21. Martin G: The roles of FGFs in the early development of vertebrate
limbs. Genes Dev 1998, 12:1571–1586.
22. DeVore DL, Horvitz HR, Stern MJ: An FGF receptor signaling
pathway is required for the normal-cell migrations of the sex
myoblasts in C-elegans hermaphrodites. Cell 1995, 83:611–620.
23. Glazer L, Shilo B-Z: The Drosophila FGF-R homolog is expressed
in the embryonic tracheal system and appears to be required for
directed tracheal cell extension. Genes Dev 1991, 5:697–705.
24. DeMoerlooze L, Dickson C: Skeletal disorders associated with
fibroblast growth-factor receptor mutations. Curr Opin Genet Dev
1997, 7:378–385.
25. Nusse R, Varmus HE: Many tumors induced by the mouse
mammary tumor virus contain a provirus integrated in the same
region of the host genome. Cell 1982, 31:99–109.
26. Nusse R, Brown A, Papkoff J, et al: A new nomenclature for int-1
and related genes: the Wnt gene family. Cell 1991, 64:231–232.
27. Peters G, Brookes S, Smith R, Dickson C: Tumorigenesis by mouse
mammary tumor virus: evidence for a common region for provirus
integration in mammary tumors. Cell 1983, 33:369–377.
28. Peters G, Lee A, Dickson C: Concerted activation of two potential
proto-oncogenes in carcinomas induced by mouse mammary
tumour virus. Nature 1986, 320:628–631.
29. Stamp G, Fantl V, Poulsom R, et al: Nonuniform expression of a
mouse mammary tumor virus-driven int-2/Fgf-3 transgene in
pregnancy-responsive breast tumors. Cell Growth Differ 1992, 3:
929–938.
30. Ornitz D, Cardiff R, Kuo A, Leder P: Int-2, an autocrine and/or ultra-
short-range effector in transgenic mammary tissue transplants. J
Natl Cancer Inst 1992, 84:887–892.
31. Muller W, Lee F, Dickson C, et al: The int-2 gene product acts as an
epithelial growth factor in transgenic mice. EMBO J 1990, 9:907–
913.
32. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE:
Expression of the int-1 gene in transgenic mice is associated with
mammary gland hyperplasia and adenocarcinomas in male and
female mice. Cell 1988, 55:619–625.
33. Kwan H, Pecenka V, Tsukamoto A, et al: Transgenes expressing the
wnt-1 and int-2 protooncogenes cooperate during mammary car-
cinogenesis in doubly transgenic mice. Mol Cell Biol 1992, 12:
147–154.
34. Shackleford GM, MacArthur CA, Kwan HC, Varmus HE: Mouse
mammary-tumor virus-infection accelerates mammary carcino-
genesis in wnt-1 transgenic mice by insertional activation of int-
2/fgf-3 and hst/fgf-4. Proc Natl Acad Sci USA 1993, 90:740–744.
35. MacArthur CA, Shankar DB, Shackleford GM: FGF-8, activated by
proviral insertion, cooperates with the wnt-1 transgene in murine
mammary tumorigenesis. J Virol 1995, 69:2501–2507.
36. Lammie GA, Peters G: Chromosome 11q13 abnormalities in
human cancer. Cancer Cells 1991, 3:413–420.
37. Penault-Llorca F, Bertucci F, Adelaide J, et al: Expression of FGF and
FGF receptor genes in human breast-cancer. Int J Cancer 1995,
61:170–176.
38. Relf M, LeJeune S, Scott P, et al: Expression of the angiogenic
factors vascular endothelial cell growth factor, acidic and basic
fibroblast growth factor, tumor growth factor b b-1, platelet-derived
endothelial cell growth factor, placenta growth factor, and
pleiotrophin in human primary breast cancer and its relation to
angiogenesis. Cancer Res 1997, 57:963–969.
39. Smith K, Fox SB, Whitehouse R, et al: Upregulation of basic fibrob
• last growth factor in breast carcinoma and its relationship to vas-
cular density, oestrogen receptor, epidermal growth factor recep-
tor and survival. Ann Oncol 1999, 10:707–713.
This is a recent study of FGF-2 expression in human breast tumours,
showing its expression was restricted to the stroma, and also that there was
no observable relationship to microvessel count or EGF receptor status.
40. Colomer R, Aparicio J, Monero S, et al: Low levels of basic fibroblast
growth factor (bFGF) are associated with a poor pronosis in
human breast carcinoma. Br J Cancer 1997, 76:1215–1220.
41. Anandappa SY, Winstanley JHR, Leinster S, et al: Comparative
expression of fibroblast growth-factor messenger-RNAs in benign
and malignant breast disease. Br J Cancer 1994, 69:772–776.
42. Luqmani Y, Graham M, Coombes R: Expression of basic fibroblast
growth factor, FGFR1 and FGFR2 in normal and malignant human
breast, and comparison with other normal tissues. Br J Cancer
1992,  66:271–280.
http://breast-cancer-research.com/content/2/3/19143. Yiangou C, Gomm JJ, Coope RC, et al: Fibroblast growth factor-2 in
breast cancer occurrence and prognostic significance. Br J Cancer
1997, 75:28–33.
44. Linder C, Bystom P, Engel G, et al: Correlation between basic
fibroblast growth factor immunostaining of stromal cells and
stromelysin-3 mRNA expression in human breast carcinoma. Br J
Cancer 1998, 77:941–945.
45. Smith J, Yelland A, Baillie R, Coombes RC: Acidic and basic fibrob-
last growth-factors in human breast-tissue. Eur J Cancer 1994,
30A:496–503.
46. Bansal GS, Yiangou C, Coope RC, et al: Expression of fibroblast
growth-factor-1 is lower in breast-cancer than in the normal
human breast. Br J Cancer 1995, 72:1420–1426.
47. Coope RC, Browne PJ, Yiangou C, et al: The location of acidic
fibroblast growth-factor in the breast is dependent on the activity
of proteases present in breast-cancer tissue. Br J Cancer 1997,
75:1621–1630.
48. Marsh SK, Bansal GS, Zammit C, et al: Increased expression of
fibroblast growth factor 8 in human breast cancer. Oncogene
1999,  18:1053–1060.
49. Tanaka A, Furuya A, Yamasaki M, et al: High-frequency of fibroblast-
growth-factor (FGF)-8 expression in clinical prostate cancers and
breast tissues, immunohistochemically demonstrated by a newly
established neutralizing monoclonal-antibody against FGF-8.
Cancer Res 1998, 58:2053–2056.
50. Theillet C, Adelaide J, Louason G, et al: FGFR1 and PLAT genes and
DNA amplification at 8p12 in breast and ovarian cancers. Genes
Chromosomes Cancer 1993, 7:219–226.
51. Adnane J, Gaudray P, Dionne C, et al: BEK and FLG, two receptors
to members of the FGF family, are amplified in subsets of human
breast cancers. Oncogene 1991, 6:659–663.
52. Blanckaert VD, Hebbar M, Louchez MM, et al: Basic fibroblast-
growth-factor receptors and their prognostic value in human
breast-cancer. Clin Cancer Res 1998, 4:2939–2947.
53. Cappellen D, De Oliveira C, Ricol D, et al: Frequent activating 
•• mutations of FGFR3 in human bladder and cervix carcinoma.
Nature Genet 1999, 23:18–20.
This paper provides compelling evidence that FGF signalling is an important
factor in a significant proportion of cervical and bladder cancers. Point
mutations were found in the FGFR3 gene and were shown to be the same
as those associated with the autosomal-dominant skeletal disorder, thana-
trophic dysplasia.
54. Neilson KM, Friesel R: Ligand-independent activation of fibroblast
growth-factor receptors by point mutations in the extracellular,
transmembrane, and kinase domains. J Biol Chem 1996, 271:
25049–25057.
55. Naski MC, Wang Q, Xu JS, Ornitz DM: Graded activation of fibrob-
last growth-factor receptor 3 by mutations causing achondropla-
sia and thanatophoric dysplasia. Nature Genet 1996, 13:233–237.
56. Webster MK, Donoghue DJ: Constitutive activation of fibroblast
growth-factor receptor-3 by the transmembrane domain point
mutation found in achondroplasia. EMBO J 1996, 15:520–527.
57. Jackson D, Bresnick J, Rosewell I, et al: Fibroblast growth-factor
receptor signaling has a role in lobuloalveolar development of the
mammary-gland. J Cell Sci 1997, 110:1261–1268.
58. Lee FS, Lane TF, Kuo A, Shackleford GM, Leder P: Insertional muta-
genesis identifies a member of the wnt gene family as a candi-
date oncogene in the mammary epithelium of int-2/FGF-3
transgenic mice. Proc Natl Acad Sci USA 1995, 92:2268–2272.
59. Gallahan D, Kozak C, Callahan R: A new common integration region
(int-3) for mouse mammary tumor virus on mouse chromosome
17. J Virol 1987, 61:218–220.
60. Peters G, Brookes S, Smith R, Placzek M, Dickson C: The mouse
homolog of the hst/k-FGF gene is adjacent to int-2 and activated
by proviral insertion in some virally induced mammary tumors.
Proc Natl Acad Sci USA 1989, 86:5678–5682.
61. Roelink H, Wagenaar E, Lopes de Silva S, Nusse R: Wnt-3, a gene
activated by proviral insertion in mouse mammary tumors, is
homologous to int-1/wnt-1 and is normally expressed in mouse
embryos and adult brain. Proc Natl Acad Sci USA 1990, 87:4519–
4523.
Authors’ affiliation: Imperial Cancer Research Fund, London, UK
Correspondence: Clive Dickson, Imperial Cancer Research Fund,
44 Lincoln’s Inn Fields, London WC2A 3PX, UK.
Tel: +44 020 7269 3336; Fax: +44 020 7269 3094;
e-mail: dickson@icrf.icnet.uk
Breast Cancer Research    Vol 2 No 3 Dickson et al